BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

25328

533573

APLLTD

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ALEMBIC PHARMA LTD performance

Today’s low

Today’s high

₹ 983.30 ₹ 1010.10
₹ 986.20

52 week low

52 week high

₹ 725.20 ₹ 1303.90
₹ 986.20

Open Price

₹ 999.70

Prev. Close

₹ 1000.50

Volume (Shares)

64397.00

Total traded value

₹ 635.08

Upper Circuit

₹ 1200.60

Lower Circuit

₹ 800.40

info

ALEMBIC PHARMA LTD Share Price Update

As of the latest trading session, ALEMBIC PHARMA LTD share price is currently at ₹ 985.6, which is down by ₹ -14.90 from its previous closing. Today, the stock has fluctuated between ₹ 983.30 and ₹ 1010.10. Over the past year, ALEMBIC PHARMA LTD has achieved a return of 1.48 %. In the last month alone, the return has been 1.08 %. Read More...

Investment Returns

Over 1 Month 1.08% Over 3 Months 17.85% Over 6 Months -6.12% Over 1 Year 1.48%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ALEMBIC PHARMA LTD fundamentals


  • Market cap (Cr)

    19,385.10

  • P/E Ratio (TTM)

    39.07

  • Beta

    0.48

  • Book Value / share

    264.27

  • Return on equity

    9.96%

  • EPS (TTM)

    24.87

  • Dividend yield

    1.10%

  • Net profit/quarter (Cr)

    75.34

info icon alternate text
  • Market cap (Cr)

    19,418.50

  • P/E Ratio (TTM)

    39.07

  • Beta

    0.42

  • Book Value / share

    264.27

  • Return on equity

    9.96%

  • EPS (TTM)

    24.87

  • Dividend yield

    1.10%

  • Net profit/quarter (Cr)

    75.34

info icon alternate text

ALEMBIC PHARMA LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 1570.64
Operating Expense 1492.29
Net Profit 75.34
Net Profit Margin (%) 4.79
Earnings Per Share (EPS) 3.83
EBITDA 183.87
Effective Tax Rate (%) 17.71
Particulars DEC 2024 (Values in Cr)
Revenue 1406.09
Operating Expense 1317.74
Net Profit 85.81
Net Profit Margin (%) 6.10
Earnings Per Share (EPS) 4.37
EBITDA 195.29
Effective Tax Rate (%) 17.33
Particulars SEP 2024 (Values in Cr)
Revenue 1580.35
Operating Expense 1409.26
Net Profit 165.78
Net Profit Margin (%) 10.49
Earnings Per Share (EPS) 8.43
EBITDA 288.42
Effective Tax Rate (%) 17.11
Particulars JUN 2024 (Values in Cr)
Revenue 1475.56
Operating Expense 1265.51
Net Profit 176.19
Net Profit Margin (%) 11.94
Earnings Per Share (EPS) 8.96
EBITDA 294.57
Effective Tax Rate (%) 17.35
Particulars MAR 2024 (Values in Cr)
Revenue 1474.55
Operating Expense 1265.61
Net Profit 201.87
Net Profit Margin (%) 13.69
Earnings Per Share (EPS) 10.27
EBITDA 295.40
Effective Tax Rate (%) 6.61
Particulars MAR 2025 (Values in Cr)
Revenue 6032.63
Operating Expense 5484.79
Net Profit 503.12
Net Profit Margin (%) 8.33
Earnings Per Share (EPS) 25.60
EBITDA 962.14
Effective Tax Rate (%) 17.33
Particulars MAR 2024 (Values in Cr)
Revenue 5874.06
Operating Expense 5201.15
Net Profit 666.48
Net Profit Margin (%) 11.34
Earnings Per Share (EPS) 33.91
EBITDA 1029.84
Effective Tax Rate (%) 5.36
Particulars MAR 2023 (Values in Cr)
Revenue 5149.00
Operating Expense 4806.62
Net Profit 346.73
Net Profit Margin (%) 6.73
Earnings Per Share (EPS) 17.64
EBITDA 667.88
Effective Tax Rate (%) -0.23
Particulars MAR 2022 (Values in Cr)
Revenue 5035.41
Operating Expense 4428.54
Net Profit 543.55
Net Profit Margin (%) 10.79
Earnings Per Share (EPS) 27.65
EBITDA 959.95
Effective Tax Rate (%) 17.39
Particulars MAR 2021 (Values in Cr)
Revenue 5051.44
Operating Expense 3718.36
Net Profit 1175.39
Net Profit Margin (%) 23.26
Earnings Per Share (EPS) 60.67
EBITDA 1581.96
Effective Tax Rate (%) 17.02
Particulars MAR 2025 (Values in Cr)
Book Value / Share 264.10
ROE % 11.63
ROCE % 13.08
Total Debt to Total Equity 0.18
EBITDA Margin 15.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 245.14
ROE % 13.40
ROCE % 12.93
Total Debt to Total Equity 0.13
EBITDA Margin 15.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 222.36
ROE % 7.12
ROCE % 7.20
Total Debt to Total Equity 0.15
EBITDA Margin 12.03
Particulars MAR 2022 (Values in Cr)
Book Value / Share 266.47
ROE % 10.11
ROCE % 10.91
Total Debt to Total Equity 0.13
EBITDA Margin 17.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share 257.80
ROE % 26.91
ROCE % 25.51
Total Debt to Total Equity 0.28
EBITDA Margin 29.07
Particulars MAR 2025 (Values in Cr)
Book Value / Share 264.30
ROE % 9.96
ROCE % 11.40
Total Debt to Total Equity 0.17
EBITDA Margin 15.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 249.75
ROE % 14.30
ROCE % 14.13
Total Debt to Total Equity 0.13
EBITDA Margin 17.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 224.59
ROE % 7.15
ROCE % 6.98
Total Debt to Total Equity 0.15
EBITDA Margin 12.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 269.16
ROE % 10.46
ROCE % 11.38
Total Debt to Total Equity 0.12
EBITDA Margin 19.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 259.57
ROE % 25.96
ROCE % 24.67
Total Debt to Total Equity 0.27
EBITDA Margin 30.26
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 90.10
Total Assets 7772.93
Total Liabilities 7772.93
Total Equity 5189.52
Share Outstanding 196563124
Price to Book Ratio 3.52
Return on Assets (%) 7.50
Return on Capital (%) 9.14
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 126.57
Total Assets 6445.58
Total Liabilities 6445.58
Total Equity 4818.20
Share Outstanding 196563124
Price to Book Ratio 3.93
Return on Assets (%) 9.55
Return on Capital (%) 11.73
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 82.27
Total Assets 6182.83
Total Liabilities 6182.83
Total Equity 4370.47
Share Outstanding 196563124
Price to Book Ratio 2.21
Return on Assets (%) 5.53
Return on Capital (%) 6.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 69.43
Total Assets 7122.03
Total Liabilities 7122.03
Total Equity 5237.54
Share Outstanding 196563124
Price to Book Ratio 2.75
Return on Assets (%) 7.31
Return on Capital (%) 8.88
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 105.84
Total Assets 6708.98
Total Liabilities 6708.98
Total Equity 5066.97
Share Outstanding 196563124
Price to Book Ratio 3.72
Return on Assets (%) 17.08
Return on Capital (%) 20.6
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 20.85
Total Assets 7556.27
Total Liabilities 7556.27
Total Equity 5194.74
Share Outstanding 196563124
Price to Book Ratio 3.52
Return on Assets (%) 6.65
Return on Capital (%) 7.94
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 26.49
Total Assets 6398.55
Total Liabilities 6398.55
Total Equity 4908.91
Share Outstanding 196563124
Price to Book Ratio 3.93
Return on Assets (%) 10.41
Return on Capital (%) 12.51
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 28.46
Total Assets 6130.42
Total Liabilities 6130.42
Total Equity 4414.30
Share Outstanding 196563124
Price to Book Ratio 2.21
Return on Assets (%) 5.65
Return on Capital (%) 6.87
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 21.90
Total Assets 7074.04
Total Liabilities 7074.04
Total Equity 5290.34
Share Outstanding 196563124
Price to Book Ratio 2.75
Return on Assets (%) 7.68
Return on Capital (%) 9.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 61.44
Total Assets 6643.47
Total Liabilities 6643.47
Total Equity 5101.81
Share Outstanding 196563124
Price to Book Ratio 3.72
Return on Assets (%) 16.50
Return on Capital (%) 19.58
Particulars MAR 2025 (Values in Cr)
Net Income 707.18
Cash from Operations 159.35
Cash from Investing -568.41
Cash from Financing 443.73
Net change in Cash -36.73
Free Cash Flow 722.97
Particulars MAR 2024 (Values in Cr)
Net Income 631.83
Cash from Operations 823.05
Cash from Investing -320.60
Cash from Financing -437.87
Net change in Cash 44.73
Free Cash Flow 1150.52
Particulars MAR 2023 (Values in Cr)
Net Income 354.59
Cash from Operations 784.64
Cash from Investing -447.60
Cash from Financing -261.96
Net change in Cash 14.39
Free Cash Flow 1228.05
Particulars MAR 2022 (Values in Cr)
Net Income 625.39
Cash from Operations 675.78
Cash from Investing -371.97
Cash from Financing -217.35
Net change in Cash -36.97
Free Cash Flow 1101.42
Particulars MAR 2021 (Values in Cr)
Net Income 1368.08
Cash from Operations 1708.82
Cash from Investing -838.81
Cash from Financing -597.43
Net change in Cash 27.15
Free Cash Flow 2368.34
Particulars MAR 2025 (Values in Cr)
Net Income 608.59
Cash from Operations 272.22
Cash from Investing -636.06
Cash from Financing 403.61
Net change in Cash -5.90
Free Cash Flow 835.23
Particulars MAR 2024 (Values in Cr)
Net Income 704.23
Cash from Operations 782.80
Cash from Investing -329.02
Cash from Financing -445.29
Net change in Cash -1.54
Free Cash Flow 1107.32
Particulars MAR 2023 (Values in Cr)
Net Income 345.93
Cash from Operations 784.04
Cash from Investing -460.98
Cash from Financing -261.16
Net change in Cash 8.11
Free Cash Flow 1227.30
Particulars MAR 2022 (Values in Cr)
Net Income 658.01
Cash from Operations 674.06
Cash from Investing -368.72
Cash from Financing -216.64
Net change in Cash -40.10
Free Cash Flow 1096.42
Particulars MAR 2021 (Values in Cr)
Net Income 1337.74
Cash from Operations 1628.92
Cash from Investing -835.72
Cash from Financing -533.76
Net change in Cash 19.00
Free Cash Flow 2285.91
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.37 32.19 1.99 278.72 34.11 / 77.70
BLISS GVS PHARMA LTD 161.00 20.15 1.61 1697.67 105.05 / 184.95
CIPLA LTD 1488.15 23.36 3.85 120199.04 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 339.30 12.99 2.75 998.59 189.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.35 36.35 5.74 278.56 34.11 / 77.70
AMRUTAJAN HEALTH LTD 715.05 40.67 6.32 2067.25 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 9138.10 130.51 29.65 22845.25 6222.35 / 10653.05
BLISS GVS PHARMA LTD 163.05 24.93 1.62 1719.29 105.05 / 184.95

ALEMBIC PHARMA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
986.20 -1.42 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 1000.30
  • 26 Days 980.20
  • 10 Days 994.30
  • 50 Days 961.60
  • 12 Days 992.20
  • 100 Days 949.80
  • 20 Days 985.20
  • 200 Days 958.20
1003.87 PIVOT

First Support

995.43

First Resistance

1010.73

Second Support

988.57

Second Resistance

1019.17

Third Support

980.13

Third Resistance

1026.03

RSI

55.53

ADX

28.68

MACD

11.96

Williams % R

-58.12

Commodity Channel Index (CCI)

44.83

Date

2025-07-08

Week

78284.00

Same Day

54860.00

Month

97806.00

1 Year

0.48

3 Year

0.57

Over 1 Month

1.08%

down

Over 1 Year

1.48%

down

Over 3 Months

17.85%

down

Over 3 Years

10.92%

down

Over 6 Months

-6.12%

down

Over 5 Years

1.44%

down

ALEMBIC PHARMA LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
9.95%
Promoter Holdings
69.67%
FII
3.94%
DII
16.42%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nirayu Limited 7.0047035E7 (35.64%) Shareholding of Promoter and Promoter Group
Alembic Limited 5.6097544E7 (28.54%) Shareholding of Promoter and Promoter Group
Dsp Midcap Fund 9037500.0 (4.6%) Public Shareholding
Life Insurance Corporation Of India 8495125.0 (4.32%) Public Shareholding
Chirayu Ramanbhai Amin 4192529.0 (2.13%) Shareholding of Promoter and Promoter Group
Kotak Small Cap Fund 3428435.0 (1.74%) Public Shareholding
Malika Chirayu Amin 3005730.0 (1.53%) Shareholding of Promoter and Promoter Group
Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund 1979645.0 (1.01%) Public Shareholding
Udit Chirayu Amin 1006980.0 (0.51%) Shareholding of Promoter and Promoter Group
Shaunak Chirayu Amin 1006980.0 (0.51%) Shareholding of Promoter and Promoter Group
Pranav Chirayu Amin 1009800.0 (0.51%) Shareholding of Promoter and Promoter Group
Gallup Trust (pranav Chirayu Amin) 100100.0 (0.05%) Shareholding of Promoter and Promoter Group
Chirayu Ramanbhai Amin Huf 106737.0 (0.05%) Shareholding of Promoter and Promoter Group
Naintara Shaunak Amin 80000.0 (0.04%) Shareholding of Promoter and Promoter Group
Inaaya Shaunak Amin 80000.0 (0.04%) Shareholding of Promoter and Promoter Group
Satori Trust (chirayu Ramanbhai Amin) 50100.0 (0.03%) Shareholding of Promoter and Promoter Group
Krupa Shaunak Amin 50100.0 (0.03%) Shareholding of Promoter and Promoter Group
Barkha Pranav Amin 50100.0 (0.03%) Shareholding of Promoter and Promoter Group
Samira Pranav Amin 30000.0 (0.02%) Shareholding of Promoter and Promoter Group
Ranvir Pranav Amin 30000.0 (0.02%) Shareholding of Promoter and Promoter Group
Tishya Udit Amin 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Viramya Packlight Llp 900.0 (0.0%) Shareholding of Promoter and Promoter Group
Cra Family Trust (chirayu Ramanbhai Amin) 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Grace Star Trust (shaunak Chirayu Amin) 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Shreno Limited 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Laksh Trust (chirayu Ramanbhai Amin) 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Virsad Family Trust (pranav Chirayu Amin) 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Laburnum Family Trust (chirayu Ramanbhai Amin) 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Uday Education Society (biniti Trivedi) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Bhailal Amin General Hospital (chirayu Ramanbhai Amin) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ujjval Vidyalaya (malika Chirayu Amin) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Utkarsh Vidyakendra (malika Chirayu Amin) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Arogyavardhini Society (malika Chirayu Amin) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vidyanidhi Trust (malika Chirayu Amin) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shreno Engineering Limited 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Shreno Publications Limited 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Alembic City Limited 100.0 (0.0%) Shareholding of Promoter and Promoter Group
Paushak Limited 855.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

ALEMBIC PHARMA LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
15 Jul 2024 11.0 Final 15 Jul 2024 Equity shares
28 Jul 2023 8.0 Final 28 Jul 2023 Equity shares
17 Aug 2022 10.0 Interim 18 Aug 2022 Equity shares
19 Jul 2021 14.0 Final 21 Jul 2021 Equity shares
16 Mar 2020 3.0 Special 17 Mar 2020 Equity shares
16 Mar 2020 7.0 Interim 17 Mar 2020 Equity shares
18 Jul 2019 5.5 Final 22 Jul 2019 Equity shares
18 Jul 2018 4.0 Final 20 Jul 2018 Equity shares
11 Jul 2017 4.0 Final 13 Jul 2017 Equity shares
20 Jul 2016 4.0 Final 22 Jul 2016 Equity shares
22 Jul 2015 3.5 Final 24 Jul 2015 Equity shares
17 Jul 2014 3.0 Final 21 Jul 2014 Equity shares
29 Jul 2013 2.5 Final 31 Jul 2013 Equity shares
31 Jul 2012 1.4 Final 02 Aug 2012 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
28 Jul 2023 8.0 Final 28 Jul 2023 Equity shares
17 Aug 2022 10.0 Interim 18 Aug 2022 Equity shares
19 Jul 2021 14.0 Final 21 Jul 2021 Equity shares
16 Mar 2020 3.0 Special 17 Mar 2020 Equity shares
16 Mar 2020 7.0 Interim 17 Mar 2020 Equity shares
18 Jul 2019 5.5 Final 22 Jul 2019 Equity shares
18 Jul 2018 4.0 Final 20 Jul 2018 Equity shares
11 Jul 2017 4.0 Final 13 Jul 2017 Equity shares
20 Jul 2016 4.0 Final 22 Jul 2016 Equity shares
22 Jul 2015 3.5 Final 24 Jul 2015 Equity shares
17 Jul 2014 3.0 Final 21 Jul 2014 Equity shares
29 Jul 2013 2.5 Final 31 Jul 2013 Equity shares
31 Jul 2012 1.4 Final 02 Aug 2012 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ALEMBIC PHARMA LTD Share Price

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India.

Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010.

In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.

In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange.

During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA.

During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA.

During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.'.

During 2015, the company's associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day-1. Also during the year, the company transitioned to own marketing in the US.

In 2016, the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets.

In July 2017, Alembic Pharmaceuticals inaugurated a state of the art anti-cancer manufacturing facility at Panelav, Halol, Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US, Middle East, North Africa, Australia and South Africa.

On 1 November 2017, Alembic Pharmaceuticals announced that through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey, USA based generic drug developer Orit Laboratories LLC along with real estate, owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a state-of-the-art 8,600 square feet R&D and pilot manufacturing facility, Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs, Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists.

On 21 March 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at the company's formulation facility located at Panelav, Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations, which will be submitted to the US FDA shortly.

On 24 April 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s.

In 2019, the Company launched 9 new products in the US.

In 2021, Rhizen's out-licenced, novel molecule 'Umbralicib (UKONIQ)' was launched by TG Therapeutics USA.

During the year 2021-22, the Company acquired the balance 40% stake held by the joint venture partner in Aleor Dermaceuticals
Limited (Aleor) and pursuant to said acquisition, Aleor became a wholly owned subsidiary of the Company.

The wholly owned subsidiary, Aleor Dermaceuticals Limited got amalgamated with the Company, making the Scheme of Arrangement effective from 29th August, 2022.

During FY23, the Company filed 20 ANDAs and received approvals for 22 ANDAs taking the total filed ANDAs to 245 as on March 31, 2023.
At Panelav, Alembic set up dedicated blocks (F2) for manufacturing oncology products which was approved by the US FDA in 2022. The Company launched various new products, especially in the gynecology and anti-diabetic spaces; it launched 33 new SKUs in FY23, of which 66% were in specialty therapies. It established a subsidiary in Chile to gain a strong foothold in the large and growing Latin American markets. It opened a scientific office in the UAE to capitalise on the opportunities emerging from the GCC nations.

Alembic launched 27 new products, including 18 oncology, derma and ophthalmic product in FY24. The Company launched products in speciality and animal health space in FY24. It formed a subsidiary in the UAE by setting up a scientific office during the year.

The US Generic business scaled volumes to counter price erosion via strengthening the supply chain in FY 25. It has launched 16 new products, of which 9 OSD, 2 Injectable, 2 Ophthalmic, 3 Dermatology.

Parent organization Indian Private
NSE symbol APLLTD
Founded 2010
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Alembic Pharmaceuticals Ltd?

Answer Field

Alembic Pharmaceuticals Ltd share price is for NSE ₹ 985.60 & for BSE ₹ 986.30 as on Jul 09 2025 03:30 PM.

What is the Market Cap of Alembic Pharmaceuticals Ltd Share?

Answer Field

The market cap of Alembic Pharmaceuticals Ltd for NSE ₹ 19,373.26 & for BSE ₹ 19,387.02 as on Jul 09 2025 03:30 PM.

What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Alembic Pharmaceuticals Ltd for NSE is ₹ 1,303.90 and ₹ 725.20 and for BSE is ₹ 1,296.15 and ₹ 725.60.

What is 1 year return for Alembic Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 1.48%.

What is the P/E Ratio of Alembic Pharmaceuticals Ltd Share?

Answer Field

As on Jul 09 2025 03:30 PM the price-to-earnings (PE) ratio for Alembic Pharmaceuticals Ltd share is 39.07.

What is the PB ratio of Alembic Pharmaceuticals Ltd Share?

Answer Field

As on Jul 09 2025 03:30 PM, the price-to-book (PB) ratio for Alembic Pharmaceuticals Ltd share is 264.27.

How to Buy Alembic Pharmaceuticals Ltd Share?

Answer Field

You can trade in Alembic Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Alembic Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Alembic Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Alembic Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|